Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States. - Gordan LN; Bensimon AG; Mu F; Kim N; Wu B; Lin D; Paner A; Fowler J; Marshall A; Van Sanden S; Ammann E; Goble J; et al. (Journal of medical economics, 2025)